Literature DB >> 18282619

A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats.

Samantha L McLean1, Jonathan P Beck, Marie L Woolley, Joanna C Neill.   

Abstract

RATIONALE: The NMDA receptor antagonist, phencyclidine (PCP), has been shown to induce symptoms characteristic of schizophrenia. A loss in executive function and the ability to shift attention between stimulus dimensions is impaired in schizophrenia; this can be assessed in rodents by the perceptual attentional set-shifting task.
OBJECTIVE: The aim of this study was to investigate whether the deficits induced by sub-chronic PCP in attentional set-shifting could be reversed by sub-chronic administration of clozapine, risperidone or haloperidol.
METHODS: Adult female hooded-Lister rats received sub-chronic PCP (2 mg/kg) or vehicle (1 ml/kg) i.p. twice daily for 7 days, followed by a 7-day washout period. PCP-treated rats then received clozapine, risperidone, haloperidol or vehicle once daily for 7 days and were then tested in the perceptual set-shifting task.
RESULTS: PCP significantly (p<0.01) increased the number of trials to reach criterion in the EDS phase when compared to vehicle and this deficit was significantly (p<0.01) attenuated by sub-chronic clozapine (2.5 mg/kg) and risperidone (0.2 mg/kg), but not by sub-chronic haloperidol treatment (0.05 mg/kg).
CONCLUSIONS: These data show that sub-chronic PCP produced a robust deficit within the EDS phase in the attentional set-shifting task, in female rats. Atypical antipsychotics, clozapine and risperidone, but not the classical agent, haloperidol, significantly improved the PCP-induced cognitive deficit.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18282619     DOI: 10.1016/j.bbr.2007.12.029

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  33 in total

Review 1.  TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.

Authors:  Kazunori Suzuki; Haruhide Kimura
Journal:  CNS Neurosci Ther       Date:  2018-01-09       Impact factor: 5.243

2.  Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased.

Authors:  Sam A Barnes; Jared W Young; Jo C Neill
Journal:  Neuropharmacology       Date:  2011-05-05       Impact factor: 5.250

Review 3.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

4.  Modeling deficits in attention, inhibition, and flexibility in HAND.

Authors:  Landhing M Moran; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neuroimmune Pharmacol       Date:  2014-04-25       Impact factor: 4.147

5.  In a Model of Neuroinflammation Designed to Mimic Delirium, Quetiapine Reduces Cortisol Secretion and Preserves Reversal Learning in the Attentional Set Shifting Task.

Authors:  Zyad J Carr; Lauren Miller; Victor Ruiz-Velasco; Allen R Kunselman; Kunal Karamchandani
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-22       Impact factor: 4.147

6.  The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia.

Authors:  Ayan Ghoshal; P Jeffrey Conn
Journal:  Future Neurol       Date:  2015

7.  Differential effects of 5-HT(2A) and 5-HT(2C) receptor blockade on strategy-switching.

Authors:  Phillip M Baker; Jennifer L Thompson; John A Sweeney; Michael E Ragozzino
Journal:  Behav Brain Res       Date:  2011-01-12       Impact factor: 3.332

8.  In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.

Authors:  John P Redrobe; Morten Jørgensen; Claus T Christoffersen; Liliana P Montezinho; Jesper F Bastlund; Martin Carnerup; Christoffer Bundgaard; Linda Lerdrup; Niels Plath
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

9.  Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat.

Authors:  Samantha L McLean; Marie L Woolley; Dave Thomas; Joanna C Neill
Journal:  Psychopharmacology (Berl)       Date:  2009-07-21       Impact factor: 4.530

10.  The protective effect of olanzapine on ketamine induced cognitive deficit and increased NR1 expression in rat model of schizophrenia.

Authors:  Ghada S Mahmoud; Ghada Hosny; Sally A Sayed
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2021-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.